Synthesis, Structure and Antitumour Properties of a New 1,2-Propylenediaminetetraacetate-Ruthenium(III) Compound
1995
New Ruthenium Compound with Antitumor Properties
publication
Evidence: moderate
Author Information
Author(s): R. Vilaplana, M.A. Romero, M. Quiros, J.M. Salas, F. Gonzalez-Vilchez
Primary Institution: Universidad de Sevilla
Hypothesis
The new ruthenium complex with PDTA will exhibit significant antitumor activity against various cancers.
Conclusion
The synthesized ruthenium complex shows notable antitumor activity against several murine and human tumors.
Supporting Evidence
- The complex showed a maximum T/C value of 460 against the Ehrlich ascitic tumor.
- Cures were complete in the EAT case with long-term survivors.
- The compound was exceptionally well tolerated with no observed nephrotoxicity or liver toxicity.
Takeaway
Scientists created a new medicine using ruthenium that can help fight cancer. It works better than some other similar medicines.
Methodology
The study involved synthesizing the compound, characterizing it using various chemical analyses, and testing its antitumor activity in vivo.
Want to read the original?
Access the complete publication on the publisher's website